Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Microbix Biosystems Inc T.MBX

Alternate Symbol(s):  MBXBF

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.


TSX:MBX - Post by User

Post by wizzdumbon Mar 31, 2022 4:28pm
230 Views
Post# 34564553

Q2 2022

Q2 2022

Q2 2022 in the rear view mirror, likely another record but have to wait until mid May for publication. 

Tough month for share price but have recovered somewhat. At least we know where the new floor is. I expect slow and steady climb unless big news come out. 

Once automation is fully in place we will be talking about $10-12M revenues per quarter, not full year. It's obvious the market still doesn't believe this but I have full faith the current team can deliver. Once that happens we'll be in the $2-3 range for share price and talking about 2024 full year in the $80-100M range. I won't predict share prices then. Throw in some positive developments with Kinlytic and then we can call it a party.

 

<< Previous
Bullboard Posts
Next >>